Efficacy & Safety of Pyronaridine-Artesunate Versus

Status Completed

Clinical Trial Summary

In Nigeria, malaria is the commonest reason for outpatient clinic attendance in childhood and is responsible for about 20% of childhood deaths. The emergence of strains of P. falciparum resistant to chloroquine and sulfadoxine-pyrimethamine led to severe worsening of morbidity and mortality from malaria. As a result of resistance to previously used monotherapy, the World Health Organization (WHO) in 2001, recommended that malaria-endemic countries experiencing drug-resistant malaria infection adopt combination therapy. Artemisinin-based combination therapy (ACT) is preferred to the non-ACT combination. In this randomized open-label clinical trial, the safety and efficacy of pyronaridine-artesunate and artemether-lumefantrine in the treatment of malaria among children aged 3 to 144 months who have microscopically confirmed symptomatic Plasmodium falciparum malaria were compared. The study was carried out at the Oni Memorial Children's Hospital, Ring Road Ibadan. One hundred and seventy-two children between 3 and 120 months who meet the inclusion criteria will be enrolled after obtaining written or witnessed signed informed consent from the parents or guardian. A detailed history and physical examination were carried out on each enrollee. Finger prick blood samples were taken from each enrolee for thick blood smear for malaria parasite, haematocrit, and blood spots on filter paper. Five millilitres of venous blood will be taken from an arm vein for baseline liver function tests, creatinine, and random blood glucose on days 0, 3, 7 and 28. Enrollees were randomized into one of two groups. Group one received pyronaridine-artesunate while group two received artemether-lumefantrine at standard doses. Enrollees were seen daily from days 0-3, and on days 7, 14, 21 and 28. Study drugs were administered supervised at standard dosage on days 0, 1, and 2. History taking, physical examination and blood smears were done at each contact time. Special attention will be paid to adverse effects. Parasite clearance time, fever clearance time and cure rates were compared between the two groups.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05192265
Study type	Interventional
Source	University of Ibadan
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	May 20, 2019
Completion date	December 23, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04577066` - Safety and Preliminary Protective Efficacy of Genetically Attenuated GA2 Parasites.	Phase 1/Phase 2
Completed	`NCT01883609` - A Safety and Efficacy Study of ChAd63/MVA METRAP + RTS,S	Phase 1/Phase 2
Completed	`NCT00593398` - Malarial Immunity in Pregnant Cameroonian Women
Completed	`NCT01659281` - Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand	N/A
Completed	`NCT00074841` - Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India	Phase 2/Phase 3
Recruiting	`NCT04416945` - Targeting High Risk Populations With Enhanced Reactive Case Detection in Southern Lao Peoples Democratic Republic	N/A
Completed	`NCT00314899` - Fetal Immunity to Falciparum Malaria
Completed	`NCT02867059` - SJ733 Induced Blood Stage Malaria Challenge Study	Phase 1
Completed	`NCT00701961` - Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy	Phase 2/Phase 3
Completed	`NCT00338520` - Hyperphenylalaninemia in Cerebral Malaria	N/A
Completed	`NCT00707200` - The Cytoadherence in Pediatric Malaria (CPM) Study	N/A
Completed	`NCT00393757` - Malaria Transmission and Immunity in Highland Kenya
Completed	`NCT03783299` - Targeted Active Case Detection Among High Risk Populations in Southern Lao Peoples Democratic Republic	Phase 4
Completed	`NCT02614404` - Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria	Phase 1
Completed	`NCT00358332` - Phase I Pediatric FMP2.1/AS02A Trial in Mali	Phase 1
Completed	`NCT00730782` - Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers	Phase 1
Completed	`NCT00349713` - FMP2.1 Trial in Bandiagara, Mali	Phase 1
Recruiting	`NCT05052502` - Targeting High Risk Populations With Enhanced Reactive Focal Mass Drug Administration in Thailand	N/A
Completed	`NCT04093765` - Mass Screening and Treatment for Reduction of Falciparum Malaria	N/A
Completed	`NCT03764527` - Tolerability and Efficacy of Artemether-Lumefantrine Versus Artesunate + Amodiaquine in Zanzibar	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Efficacy and Safety of Pyronaridine-Artesunate Versus Artemether-Lumefantrine

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms